Rani Therapeutics Holdings, Inc. (RANI) News
Filter RANI News Items
RANI News Results
|Loading, please wait...|
RANI News Highlights
- RANI's 30 day story count now stands at 3.
- Over the past 28 days, the trend for RANI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RANI are KOSS, HUDI and LRN.
Latest RANI News From Around the Web
Below are the latest news stories about Rani Therapeutics Holdings Inc that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - - Company announces preliminary consolidated financial results for the fourth quarter and year ended December 31, 2021 - SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Na
Gainers: Weidai (WEI) +79%.Rani Therapeutics Holdings (RANI) +33%.Stride LRN +29%.Exela Technologies XELA +26%.Huadi International (HUDI) +21%.Koss (KOSS) +20%.Sierra (SRRA)
Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.
SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Rometty to its Board of Directors. Ms. Rometty brings significant global commercial leadership experience across a spectrum of start-ups to mature businesses in medical device, technology and pharmaceuticals. “In our effort to pioneer the fiel
Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]
The parade to Wall Street was the biggest in decades, if ever, in 2021. But the portion of newly public companies that actually posted positive returns was a small fraction. Among the Bay Area contingent, these did the best.
Shares of Rani Therapeutics Holdings Inc (NASDAQ:RANI) have been assigned an average recommendation of Buy from the six research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages 
Rani Therapeutics Holdings Inc (NASDAQ:RANI)s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.94, but opened at $16.18. Rani Therapeutics shares last traded at $16.88, with a volume of 201 shares. Several equities research analysts have commented on the company. Stifel Nicolaus assumed coverage on Rani 
FY2021 Earnings Estimate for Rani Therapeutics Holdings Inc Issued By Cantor Fitzgerald (NASDAQ:RANI)
Rani Therapeutics Holdings Inc (NASDAQ:RANI) – Equities researchers at Cantor Fitzgerald lowered their FY2021 EPS estimates for Rani Therapeutics in a research note issued to investors on Monday, December 6th. Cantor Fitzgerald analyst B. Folkes now forecasts that the company will earn ($1.19) per share for the year, down from their prior estimate of ($0.76). […]
Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares gapped down prior to trading on Friday . The stock had previously closed at $25.68, but opened at $24.52. Rani Therapeutics shares last traded at $24.51, with a volume of 714 shares traded. A number of brokerages have recently commented on RANI. BTIG Research began coverage on Rani Therapeutics […]